Luminex Crossmatch in kidney transplantation.
Luminex Crossmatch
anti-HLA antibodies
crossmatch
donor-specific antibodies
kidney transplantation
Journal
Scandinavian journal of immunology
ISSN: 1365-3083
Titre abrégé: Scand J Immunol
Pays: England
ID NLM: 0323767
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
revised:
26
03
2023
received:
25
12
2022
accepted:
01
05
2023
medline:
15
6
2023
pubmed:
3
5
2023
entrez:
3
5
2023
Statut:
ppublish
Résumé
The introduction of the Luminex Crossmatch assay (LumXm) which uses Luminex bead technology, consists of extracting the donor's Human Leukocyte Antigen (HLA) molecules from their lymphocytes, and binding them to fluorescent beads that are put in contact with recipient's serum. HLA donor-specific antibodies (DSA) are detected using a fluorescent conjugate. The goal of our study is to determine the benefits of using LumXm in a renal transplantation algorithm. We tested 78 recipients' sera using the LumXm, and the results were compared with the Luminex single antigen bead assay (SAB) for all sera, as well as the Flow Cytometry Crossmatch (FCXM) for 46 sera. We compared our results with those of SAB using 3 cutoffs, the first being the manufacturer's criteria where sensitivity and specificity were at 62.5% and 91.3% respectively for HLA class 1, and 88.5% and 50.0% respectively for HLA class 2. When using the third cutoff criteria (≥2 Adjusted values + MFI [Mean fluorescence intensity] >500 + Neg MFI < 500), the sensitivity increased to 69.0% for HLA class 1 and decreased to 84.0% for HLA class 2, while the specificity increased for HLA class 1 and 2. When comparing with FCXM, the 3 assays agreed in 55.8% of results for class 1 and 2 alike. However, major discrepancies were found for two groups in HLA class 1 and one in HLA class 2. The LumXm when used with other techniques to overcome its' weak points, can provide an interesting insight into the patient's HLA-DSA profile.
Substances chimiques
Antibodies
0
HLA Antigens
0
Histocompatibility Antigens Class II
0
Histocompatibility Antigens Class I
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13279Informations de copyright
© 2023 The Scandinavian Foundation for Immunology.
Références
Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med. 1969;280:735-739.
Terasaki PI, McClelland JD. Microdroplet assay of human serum cytotoxins. Nature. 1964;204(4962):998-1000.
Fuller TC, Cosimi AB, Russell PS. Use of an antiglobulin-ATG reagent for detection of low levels of alloantibody. Improvement of allograft survival in presensitized recipients. Transplant Proc. 1978;10(2):463-466.
Kissmeyer-Nielsen F, Olsen S, Petersen VP, Fjeldborg O. Hyperacute rejection of kidney allografts associated with pre-existing humoral antibodies against donor cells. Lancet. 1966;1:662-665.
Williams GM, Hume DM, Hudson RP Jr, Morris PJ, Kano K, Milgorm F. Hyperacute renal-homograft rejection in man. N Engl J Med. 1968;279:611-618.
Scornik JC. Detection of alloantibodies by flow cytometry: relevance to clinical transplantation. Cytometry. 1995;22(4):259-263.
Maguire O, Tario JD Jr, Shanahan TC, Wallace PK, Minderman H. Flow cytometry and solid organ transplantation: a perfect match. Immunol Invest. 2014;43(8):756-774.
Leffell MS, Montgomery RA, Zachary AA. The changing role of antibody testing in transplantation. Clin Transpl. 2005;259-271.
Picascia A, Infante T, Napoli C. Luminex and antibody detection in kidney transplantation. Clin Exp Nephrol. 2012;16(3):373-381.
Billen EVA, Voorter CEM, Christiaans MHL, van den Berg-Loonen EM. Luminex donor-specific crossmatches. Tissue Antigens. 2008;71(6):507-513.
Guillaume N, Mazouz H, Piot V, Presne C, Westeel PF. Correlation between Luminex donor-specific crossmatches and levels of donor-specific antibodies in pretransplantation screening: donor-specific antibodies and Luminex donor-specific crossmatches. Tissue Antigens. 2013;82(1):16-20.
Huh KH, Kim MS, Kim HJ, et al. Renal transplantation in sensitized recipients with positive luminex and negative CDC (complement-dependent cytotoxicity) crossmatches: renal transplantation in recipients with a positive Luminex-crossmatch. Transpl Int. 2012;25(11):1131-1137.
Mahendra Narain M, David T, Puja D, Vandana L. Luminex Crossmatch for pre-transplant workup of renal transplants - 30 months experience from Indian subcontinent. Int J Transplant Res Med. 2019;5(1):039.
Caro-Oleas JL, González-Escribano MF, Toro-Llamas S, et al. Donor-specific antibody detection: comparison of single antigen assay and Luminex crossmatches. Tissue Antigens. 2010;76(5):398-403.
Vimal M, Chacko M, Basu G, Daniel D. Correlation of pretransplant donor-specific antibody assay using Luminex Crossmatch with graft outcome in renal transplant patients. Indian J Nephrol. 2017;27(5):347-352.
Narain Mishra M, Lal V. Luminex Crossmatch as a successful algorithm for post-transplant follow-up in developing nations-a study of 169 consecutive samples. J Kidney. 2015;2:2.
Chacko M, Augustin A, David V, Valson A, Daniel D. Nonspecific positivity on the Luminex Crossmatch assay for anti-human leukocyte antigen antibodies due to antibodies directed against the antibody coated beads. Indian J Nephrol. 2016;26(2):134-137.
Riethmüller S, Ferrari-Lacraz S, Müller MK, et al. Donor-specific antibody levels and three generations of crossmatches to predict antibody-mediated rejection in kidney transplantation. Transplantation. 2010;90(2):160-167.
Pandey P, Setya D, Sinha V, et al. Renal transplantation in HLA sensitized patients: traversing the immunological barrier. Ther Apher Dial. 2020;24(5):578-590.
Pandey P, Pande A, Mishra S, et al. Significance of Luminex-Crossmatch assay and its mean fluorescence intensity - a retrospective observation in 380 renal transplant cases. Pol Przegl Chir. 2022;94(2):38-48.
Chowdhry M, Makroo RN, Thakur Y, Sharma V, Singh M, Kumar M. The good, the bad, and the ugly of Luminex donor-specific crossmatch. HLA. 2018;91(6):501-506.
Chaidaroglou A, Skoura A, Degiannis D. Comparative performance evaluation of a donor-specific bead-based crossmatch technique for the detection of donor-specific anti-HLA antibodies in heart transplantation. Transplant Proc. 2013;45(5):2005-2008.
Zoet YM, Brand-Schaaf SH, Roelen DL, Mulder A, Claas FHJ, Doxiadis IIN. Challenging the golden standard in defining donor-specific antibodies: does the solid phase assay meet the expectations? Tissue Antigens. 2011;77(3):225-228.
Peräsaari JP, Jaatinen T, Merenmies J. Donor-specific HLA antibodies in predicting crossmatch outcome: comparison of three different laboratory techniques. Transpl Immunol. 2018;46:23-28.
Billen EVA, Christiaans MHL, van den Berg-Loonen EM. Clinical relevance of Luminex donor-specific crossmatches: data from 165 renal transplants. Tissue Antigens. 2009;74(3):205-212.
Mehrotra S, Sharma RK, Mayya M, et al. Luminex solid-phase crossmatch for de novo donor-specific antibodies in living-donor related transplants. Exp Clin Transplant. 2017;15(4):394-399.